Aclaris therapeutics, inc. (ACRS)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14
Cash flows from operating activities:
Net loss

-161,354

-132,738

-68,523

-48,079

-20,563

-

Net loss

-

-

-

-

-

-8,517

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

6,409

1,879

402

120

90

-

Depreciation expense

-

-

-

-

-

12

Stock-based compensation expense

16,177

20,055

14,430

6,104

891

27

Change in fair value of contingent consideration

734

1,272

-

-

-

-

Goodwill impairment charge

18,504

-

-

-

-

-

Intangible asset impairment charge

27,638

-

-

-

-

-

Payment of Confluence development milestone

-

717

-

-

-

-

Gain on sale of RHOFADE

1,850

-

-

-

-

-

Deferred taxes

-

-

-1,837

-

-

-

Write-down of equipment held for sale

-

-

-

216

289

-

Non-cash charges related to Vixen acquisition

-

-

-

2,784

-

-

Changes in operating assets and liabilities:
Accounts receivable

809

4,380

-

-

-

-

Inventory

-605

-102

-

-

-

-

Prepaid expenses and other assets

-2,628

40

4,306

8

1,269

152

Accounts payable

-3,160

6,964

4,564

1,810

-359

819

Accrued expenses

-1,967

6,792

607

2,450

552

175

Net cash used in operating activities

-96,445

-100,811

-54,663

-34,603

-20,369

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-7,636

Purchases of property and equipment

1,613

1,356

1,235

232

507

417

Acquisition of RHOFADE

-

67,122

-

-

-

-

Disposition of RHOFADE

34,186

-

-

-

-

-

Acquisition of Confluence, net of cash acquired

-

-

9,647

-

-

-

Purchases of marketable securities

137,385

161,598

197,337

148,764

82,513

5,035

Proceeds from sales and maturities of marketable securities

210,491

239,443

152,527

87,093

6,069

3,673

Net cash provided by (used in) investing activities

105,679

9,367

-55,692

-61,903

-76,951

-

Cash flows from financing activities:
Proceeds from debt financing, net of issuance costs

-

29,910

-

-

-

-

Loan amount borrowed

-30,000

-

-

-

-

-

Payment of Confluence development milestone

-

1,783

-

-

-

-

Finance lease payments

523

648

78

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-1,779

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

-

39,864

10,584

Proceeds from the issuance of stock

207

577

235

121

-

-

Net cash (used in) provided by financing activities

-30,316

128,261

100,386

116,826

96,414

-

Net increase (decrease) in cash and cash equivalents

-21,082

36,817

-9,969

20,320

-

-

Net cash provided by financing activities

-

-

-

-

-

10,584

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-906

1,169

Supplemental disclosure of non-cash investing and financing activities:
Additions to property and equipment included in accounts payable

124

161

274

11

2

91

Fair value of stock issued in connection with Confluence development milestone

-

2,215

-

-

-

-

Fair value of stock issued in connection with Confluence acquisition

-

2,131

9,675

-

-

-

Property and equipment obtained pursuant to capital lease financing arrangements

-

-

-

2,355

-

-

Offering costs included in accounts payable

-

210

20

250

-

-

Operating lease asset recorded as a result of new accounting standard

2,132

-

-

-

-

-

Accretion of convertible preferred stock to redemption value

-

-

-

-

1,764

2,054

Fair value of preferred stock purchased put option on date of issuance

-

-

-

-

-

1,039

At The Market Offering
Proceeds from issuance of common stock, net of issuance costs

-

-

19,311

-

-

-

Follow On Public Offering
Proceeds from issuance of common stock, net of issuance costs

-

100,205

80,918

98,158

-

-

Private Placement
Proceeds from issuance of common stock, net of issuance costs

-

-

-

18,547

-

-